Biohaven Ltd. (NYSE:BHVN) Shares Acquired by Northern Trust Corp

Northern Trust Corp increased its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 19.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 811,155 shares of the company's stock after buying an additional 134,879 shares during the period. Northern Trust Corp owned 0.80% of Biohaven worth $30,297,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Spire Wealth Management bought a new stake in Biohaven during the fourth quarter worth approximately $56,000. Amalgamated Bank increased its stake in Biohaven by 21.9% during the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after acquiring an additional 527 shares during the last quarter. US Bancorp DE increased its stake in Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock worth $111,000 after acquiring an additional 798 shares during the last quarter. Quarry LP bought a new stake in Biohaven during the fourth quarter worth approximately $112,000. Finally, Elkhorn Partners Limited Partnership increased its stake in Biohaven by 50.0% during the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,300 shares of the company's stock worth $123,000 after acquiring an additional 1,100 shares during the last quarter. 88.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

BHVN has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the stock a "buy" rating in a research note on Thursday, March 20th. JPMorgan Chase & Co. cut their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Robert W. Baird cut their target price on Biohaven from $60.00 to $57.00 and set an "outperform" rating on the stock in a research note on Monday, April 28th. William Blair raised Biohaven to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Royal Bank of Canada dropped their price objective on Biohaven from $61.00 to $54.00 and set an "outperform" rating on the stock in a research note on Tuesday. Thirteen equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Biohaven presently has a consensus rating of "Buy" and a consensus target price of $62.00.

Insider Buying and Selling at Biohaven

In other news, Director John W. Childs purchased 32,700 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average cost of $30.47 per share, with a total value of $996,369.00. Following the completion of the acquisition, the director now directly owns 2,320,571 shares of the company's stock, valued at approximately $70,707,798.37. This trade represents a 1.43% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 16.00% of the stock is currently owned by insiders.

Biohaven Trading Down 1.3%

Shares of BHVN stock traded down $0.20 on Friday, reaching $15.62. 1,248,063 shares of the stock were exchanged, compared to its average volume of 1,199,163. The business's 50 day moving average price is $22.57 and its 200 day moving average price is $34.55. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -1.67 and a beta of 1.18. Biohaven Ltd. has a twelve month low of $14.69 and a twelve month high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($2.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.50). Equities research analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.